CTOR

4.68% -0.059

시간 외 거래: 1.20 -0.001 -0.08%

Citius Oncology Inc (CTOR)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1173)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

최신 SEC 제출 서류

CTOR's Discussions on Twitter

CTOR을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CTOR Citius Oncology Inc	1.201	85.93M	0	0	0	0.00
ZTS Zoetis Inc	170.90	77.10B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.47	42.82B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.39	42.45B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	17.73	20.09B	16.77B	-959.00M	1.37B	-0.85
NBIX Neurocrine Biosciences Inc	151.82	15.37B	2.24B	385.90M	440.10M	3.73

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-11-27	개시	Maxim Group	Buy

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology Inc (CTOR) 재무 분석

Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

CTOR을(를) 다른 주식과 비교

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology (NASDAQ:CTOR) Trading Down 2%Time to Sell? - MarketBeat

Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - 69News WFMZ-TV

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - BioSpace

Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire

Citius Oncology to explore strategic alternatives - Yahoo Finance

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - The Malaysian Reserve

Citius Pharma Reports 2024 Financial Results and Business Update - MSN

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Yahoo Finance

Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Defense World

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve

Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com

Citius Pharmaceuticals Inc. (CTXR) reports earnings - Quartz

Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com

Major Improvements In Citius Oncology Inc (CTOR) Stock Need To Be Considered - Stocks Register

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online

“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside To Watch” - Barchart

Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Maxim Group Begins Coverage on Citius Oncology (NASDAQ:CTOR) - Defense World

Loss-Making Citius Oncology, Inc. (NASDAQ:CTOR) Expected To Breakeven In The Medium-Term - Simply Wall St

Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - Yahoo Finance

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com

Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com

Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results | CTXR Stock News - StockTitan

Citius Pharma shares hit new low after reverse stock split - Kursiv Media

CTOR stock touches 52-week low at $0.9 amid market challenges - Investing.com Canada

CTOR stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa

Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split - PR Newswire

Citius Pharmaceuticals stock hits 52-week low at $0.16 - Investing.com

Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - BioSpace

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - BioSpace

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan

Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - BioSpace

Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma

CTOR stock touches 52-week low at $1.02 amid market challenges - Investing.com India

CTOR stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa

CTOR stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa

CTOR stock touches 52-week low at $1.29 amid market challenges - Investing.com

Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com

Citius Oncology Inc (CTOR) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CTOR과 유사한 종목